Xeris Biopharma appoints brand management expert Ricki Fairley to its board of directorsProactive Investors • 03/29/23
Xeris Biopharma posts record revenue growth for fourth quarter and full-year 2022Proactive Investors • 03/08/23
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial GuidanceBusiness Wire • 03/08/23
Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023Business Wire • 02/23/23
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023Business Wire • 02/02/23
Xeris Biopharma sees FDA grant Orphan-drug exclusivity to Recorlev for treatment of Cushing's syndromeProactive Investors • 01/30/23
Xeris Biopharma to proceed with Phase II study of levothyroxine for hypothyroidismProactive Investors • 12/15/22
Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for HypothyroidismBusiness Wire • 12/15/22
New Research Partnership With Horizon Therapeutics Could Be the Next Revenue Catalyst for Xeris24/7 Wall Street • 11/29/22
Xeris Biopharma inks research collaboration and option agreement with Horizon TherapeuticsProactive Investors • 11/23/22
Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of TeprotumumabBusiness Wire • 11/23/22
Xeris Biopharma posts record 3Q revenue as more patients utilize its treatmentsProactive Investors • 11/11/22
Xeris Biopharma Reports Third Quarter 2022 Financial Results and Recent EventsBusiness Wire • 11/09/22
Xeris Biopharma (XERS) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 11/02/22
Xeris Biopharma to Report Third Quarter 2022 Financial Results on November 9, 2022Business Wire • 11/02/22